Replies to post #66559 on Biotech Values

[ThomasS]

MNTA: I was interested in the part of the presentation where the possibility of legislation enabling interchangeability with a branded drug was discussed, as part of an overall FoB Congressional bill. It sounds, again, as if MNTA has been actively lobbying the FDA towards this goal.
The acceptance of the Copaxone ANDA under the 505(j) pathway seems to dovetail with this.